Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.
about
Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsEfficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic ReviewA meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation.Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study.Ziprasidone mesylate (Geodon for injection): the first injectable atypical antipsychotic medication.Ziprasidone hydrocloride: what role in the management of schizophrenia?World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.Ziprasidone in the treatment of mania in bipolar disorder.Pharmacological management of agitation in emergency settingsIntramuscular olanzapine in the management of acute agitation.Ziprasidone: efficacy and safety in patients with bipolar disorder.Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control studyIntramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study.Strategies for successful clinical management of schizophrenia with ziprasidone.Drug safety evaluation of ziprasidone.Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment.Pharmacological management of acute and persistent aggression in forensic psychiatry settings.The psychopharmacology of violence: making sensible decisions.QT Interval Prolongation Associated with Intramuscular Ziprasidone in Chinese Patients: A Case Report and a Comprehensive Literature Review with Meta-Analysis.Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations.Assessment and management of agitation in psychiatry: Expert consensus.Tardive dyskinesia in 2 patients treated with ziprasidone.Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers.Intramuscular aripiprazole in the acute management of psychomotor agitation.Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam.
P2860
Q30984472-57532627-B3DA-494C-A886-20CBCE01C2C0Q33223628-82A93BDA-1982-4FFA-B6FC-4ADB9A217281Q33566124-905ADD7C-1EAA-490D-A5EC-0152658CD805Q33695789-B2EC3CCA-EBC2-4A5A-819A-490BC657B778Q33699874-8B076705-F0E7-49BC-B042-607F41ED1905Q33765226-A420A542-06A8-4AF0-A9BC-4158769DACDEQ33995745-41968AE6-81DA-4742-AC1B-35A43D0DC99CQ34357931-88DF93FE-6729-4C0F-8C4C-51868B05338DQ34640811-F08D70A3-9FC5-413A-A654-B828B94011F7Q34966022-B084FA1B-49CC-429D-9254-9A633A6FAAD4Q35166653-0E15948D-37A5-4F3B-9A06-522EC3A26494Q35937699-B2DA6BE2-73DE-4A1C-AADC-EFB4AF9A23EDQ36558654-39E0FE49-84CD-4AB4-A4A5-1374D506EF88Q36700337-74654049-12A2-4308-A0EA-20608BA057C5Q37145883-F081B4C5-188D-48AB-8EA0-19025791E690Q37564479-3B338728-CAC7-4BC8-B2C6-44626D1C9F85Q37775630-CF8C7292-DB00-4D26-94EA-B0B4E7B16D7EQ37844574-0F69C498-6CF2-45D3-BBBC-E174B0AA24ABQ37947687-4C30DD28-CF8C-4FA6-803E-CF73672F93F8Q37963568-4CAEDA1E-D633-4040-AA88-4EC3C5902546Q38191300-99F7075F-5C99-48BE-A779-6FA28B4B51F0Q38296631-E4D14A04-A473-478D-8040-3653BF5D3349Q38448948-E190B5A5-C281-459C-818B-39E560EEB156Q38749001-C37718F4-4CFC-4F58-B37E-4B0864A76E23Q40273544-7F4D60F1-DA14-49FB-999D-C17C9D93005BQ44142664-3A6D8435-6C42-470B-BC18-48DBBE0E66F6Q46497099-4D5C6B04-752E-440B-9A76-0C5798EFC5B1Q46703897-AD015CE1-6EF4-4B0D-AD95-C195AB7D0873Q46799836-D363A339-069F-4C41-89DF-F7621C9005B1
P2860
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Intramuscular (IM) ziprasidone ...... ouble-blind, randomized trial.
@ast
Intramuscular (IM) ziprasidone ...... ouble-blind, randomized trial.
@en
type
label
Intramuscular (IM) ziprasidone ...... ouble-blind, randomized trial.
@ast
Intramuscular (IM) ziprasidone ...... ouble-blind, randomized trial.
@en
prefLabel
Intramuscular (IM) ziprasidone ...... ouble-blind, randomized trial.
@ast
Intramuscular (IM) ziprasidone ...... ouble-blind, randomized trial.
@en
P2093
P356
P1433
P1476
Intramuscular (IM) ziprasidone ...... ouble-blind, randomized trial.
@en
P2093
P2888
P304
P356
10.1007/S002130000658
P577
2001-05-01T00:00:00Z
P5875
P6179
1028863360